Camptothecin (CPT) and its derivatives play an important role in the treatment of different malignancies.[@b1-ijn-5-463],[@b2-ijn-5-463] They all have a unique mechanism of action, targeting the nuclear enzyme of DNA topoisomerase I (topo I). CPT inhibits this enzyme by blocking the rejoining step of the cleavage/relegation reaction of topo I, resulting in accumulation of a covalent reaction intermediate, the cleavage complex. The primary mechanism of cell killing by CPT is S-specific killing through potentially lethal collision between advancing replication forks and topo-I cleavable complexes.[@b3-ijn-5-463],[@b4-ijn-5-463],[@b5-ijn-5-463] In the structure of these analogues, common features include an aromatic 5-ring system and a lactone moiety which is crucial for their antitumor activity.[@b4-ijn-5-463]

9-Nitrocamptothecin (9-NC) is a novel, lipophilic derivative of CPT which has a high antitumor activity which has been used in several clinical trial studies in order to treat advanced pancreatic carcinoma, ovarian epithelial cancer and leukemia.[@b2-ijn-5-463] Unfortunately, the lactone form depends on the pH of the medium and easily inverts to carboxylate form in alkaline pHs, especially when exposed to serum albumin proteins, which remove its antitumor properties (see [Figure 1](#f1-ijn-5-463){ref-type="fig"}).[@b4-ijn-5-463],[@b6-ijn-5-463]

Because of instability at biological pH and low water solubility, the delivery of lipophilic derivatives like 9-NC is quite challenging.[@b7-ijn-5-463] To eradicate these problems, drug delivery systems such as liposomes, nanocapsules, micellar systems, and conjugates have been used to overcome the cellular resistance and take active pharmacologic agents to the target tissue, increasing bioavailability and drug affect in target tissue, solubilizing for intravascular delivery, and improving the stability of therapeutic agents for pH hydrolysis and enzymatic degradation.[@b8-ijn-5-463],[@b9-ijn-5-463]

Polymeric nanoparticles composed of PLGA as a biocompatible and biodegradable compound have more stability and lower toxicity compared to other drug delivery systems like solid lipid nanoparticles (SLNs).[@b7-ijn-5-463] But since these structures can be easily opsonized by the mononuclear phagocytic system (MPS) due to their lipophilic surface, they have a short half-life with an *in vivo* failed function. To address this burden, some hydrophilic conjugates are used to prepare the solution, which have a hydrophilic surface with a lipophilic core in the center called the nanoparticle core shell effect.[@b10-ijn-5-463]--[@b14-ijn-5-463]

The most common formulations applied in these polymers are composed of PEG structures named copolymers; the purpose of these PEG chains is to create a barrier layer to block the adhesion of opsonins present in the blood serum, so that the particles can remain camouflaged or invisible to phagocytic cells.[@b15-ijn-5-463],[@b16-ijn-5-463]

PEGylation simply refers to the decoration of a particle surface by covalently grafting, entrapping, or adsorbing PEG chains. Also, in the case of biodegradable nanoparticles, PEG chains can be incorporated as copolymers throughout the particle so that some surface PEG chains are always available even after the degradation of surface layers.[@b15-ijn-5-463]--[@b17-ijn-5-463]

Other important points in the application of these copolymers are controlled initial release and smaller size compared to nanoparticles containing PLGA polymers which leads to increased *in vivo* stability and effect.[@b17-ijn-5-463]--[@b22-ijn-5-463]

Copolymeric nanoparticles have different characteristics in that the formation of each of them depends on the copolymer composition, molecular geometry, the length of the chain, and the method of preparation.[@b23-ijn-5-463]--[@b26-ijn-5-463]

The aim in present study was to prepare 9-NC loaded nanoparticles by PLGA-PEG copolymer and compare the physicochemical properties results with a previous study which involved the use of PLGA polymer.[@b7-ijn-5-463] The resulting 9-NC nanoparticles were characterized with regard to morphology, size, drug loading, and *in vitro* drug release.

Materials and methods
=====================

Materials
---------

9-Nitrocamptothecin (9-NC), 99.8% pure, was purchased from Yuanjian Pharmaceutical Technology Develop Co., (China). Poly(d, l-lactide-co-glycolide) (PLGA; 50:50 Mw 12000, inherent viscosity of 0.16--0.24 dl/g) and PLGA-PEG 5% (Mw 12000) were obtained from Bohringer Ingelheim Co. (Germany). Polyvinyl alcohol (PVA; Mw 30,000 Da, 87% hydrolyzed) was a gift from Mowiol (Germany). Analytical grade acetone and acetonitrile were obtained from Merck (Darmstadt, Germany). All other chemical reagents used were of pharmaceutical grade.

Preparation of nanoparticles
----------------------------

The nanoprecipitation method was employed for the formation of drug-encapsulated PLGA-PEG nanoparticles similarly to previously performed study.[@b7-ijn-5-463] Briefly, PLGA-PEG was dissolved in acetone. Then the copolymer solution containing exact amount of drug was added drop-wise (0.5 mL/min) into PVA aqueous solution (pH was adjusted to 3 by 0.1 N HCl) and stirred magnetically at room temperature until complete evaporation of the organic solvent. Next, the nanoparticle suspension was centrifuged by ultracentrifuge (XL-90 Beckman, Brea, CA) at 40,000 rpm and 4°C for 90 minutes. The separated nanoparticles were redispersed and centrifuged three times in distilled water (pH 3) in order to remove free drug and excess surfactant completely. The acidity of the medium used in this process was because of stabilizing the lactone form of 9-nitrocamptothecin. Finally, nanoparticles were dried via desiccator at room temperature for 24 hours, and then were characterized.

In this study, we evaluated the effects on drug loading of four different variable amounts of polymer, percent of emulsifier, internal phase volume, and external phase volume, to approach optimum formulation by one at a time statistical method.

Characterization of 9-NC
------------------------

### Determination of particle size

The mean size and zeta potential of nanoparticles were measured by photon correlation spectroscopy (PCS) (SEMATech), at a scattering angle of 90° and at a temperature of 25°C using samples appropriately diluted with super pure water.

### Particle morphology

The morphology of nanospheres was observed by scanning electron microscopy (SEM) (Philips, the Netherlands). Samples were coated with a thin layer of colloidal gold applied in a cathodic vacuum evaporator before observation by SEM at 20 KV.

### Differential scanning calorimetry (DSC)

The physical state of the nanoparticle components was characterized by thermal analysis in DSC-60 analyzer (Shimadzu Co., Kyoto, Japan). Samples (10 mg) were sealed into aluminum pans and heated in an inert atmosphere of nitrogen with a heat rate of 10°C/min. Calibration of the system was performed using octadecane and indium.

### X-ray diffractometry

An X-ray diffractometer, (XRD; Philips APD), was used for diffraction studies. The samples were exposed to CuKα radiation (40 kv, 20 mA) and scanned from 2° to 70°, 2θ at a step size of 0.02°, and step time of 5 S. Samples used for XRD analysis were exactly the same as those used for DSC analysis.

### Determination of drug content

Drug content was determined using a validated high-pressure liquid chromatography (HPLC) method.[@b7-ijn-5-463] Nanoparticles were dissolved in acetonitrile (2 mL) and sonicated for 2 minutes. The organic solvent was evaporated until the stream of nitrogen gas and then was dissolved in 1.5 mL mobile phase of HPLC assay.

The 1001 HPLC was equipped with an ultraviolet detector model 2700 at 370 nm (Knauer, Germany) and a column of Nucleosil-100 C18 with the mobile phase containing a mixture of acetonitrile-water (43:57, V/V, pH 3).

The amount of drug loading in nanoparticles was calculated using the following equation: $$\text{Encapsulation}~\text{efficiency}~(\%) = \frac{(\text{Amount}~\text{of}~9 - \text{NC}~\text{in}~\text{nanoparticles})}{(\text{Amount}~\text{of}~9 - \text{NC}~\text{used}~\text{in}~\text{formulation})} \times 100$$

### *In vitro* drug release

The *in vitro* drug release of nanoparticles was determined by dialysis method using Franz diffusion cell. A total of 2 mL of NP suspension in phosphate-buffered saline (PBS, 0.1M, pH 7.4) was placed in donor site and 25 mL PBS in receptor part incubated at 37°C under magnetic stirring (200 rpm). At specific time intervals, 500 μL of medium was taken and replaced with the same volume of fresh PBS. The taken samples were acidified with 5% perchloric acid before UV analysis to evaluate the total form of 9-NC (lactone and carboxylate forms). The obtained release data were evaluated by zero order, first order and Higuchi equations to assay the release kinetics. To select the best model, the relevant correlation coefficients were considerable.

Statistical analysis
--------------------

The experiments were repeated three times and the results were expressed as mean ± standard deviation. Statistical analysis was undertaken using Student's *t* test and *P* value \< 0.05 were considered statistically significant.

Results and discussion
======================

Carrier-mediated drug delivery offers a number of design opportunities to tailor a delivery route around the details of particular drugs, including their modes of action and potential side effects.[@b27-ijn-5-463],[@b28-ijn-5-463] Such carrier functions can be quite diverse, including transport to the targeted tissue, control of intracellular distribution, and protection against degradation or elimination by the mononuclear phagocytic systems (MPS).[@b29-ijn-5-463],[@b30-ijn-5-463] For instance, it has been demonstrated that Paclitaxel nanoparticles have a long time release accompanied with a small size which is so important for phagocytic systems.[@b15-ijn-5-463],[@b31-ijn-5-463]--[@b33-ijn-5-463] Also preparing NPs of tumor necrosis factor-α (TNF-α), cisplatin, indomethacin, iboprufen, and so many other drugs has shown that these carriers can deliver the drug to the tissue in the best way with the least side effects and a long time circulation in the body.[@b22-ijn-5-463],[@b34-ijn-5-463],[@b35-ijn-5-463] All these features prompted us to investigate the possibility of developing these nanoparticles as a controlled release drug formulation. In the development of new colloidal structures as circulating carriers, the assessment of their performance as drug carriers necessarily comprises the knowledge of the loaded amount of drug, its physical state and distribution inside the carrier, as well as its release kinetics and the influence of environmental factors on it.

In our previous study,[@b7-ijn-5-463] PLGA-loaded 9-NC nanoparticles were prepared by nanoprecipitation method and four different independent variables on the characteristics of nanoparticles were evaluated. The results of optimized formulations showed a narrow size distribution with a polydispersity index of 0.01%, an average diameter of 207 ± 26 nm, and a drug loading of more than 30%. The *in vitro* drug release profile showed a sustained 9-NC release up to 160 hours indicating the controlled release of 9-NC via nanoparticles.

But, since PLGA nanoparticles can be uptaken by phagocytic systems easily and have a rapid initial release (15%--20% in first 5 hours), in this study, we used PLGA-PEG for preparing nanoparticles and characterized them to be taken to the next phase of study like cytotoxicity and *in vivo* studies.

Preparation of nanoparticles
----------------------------

First formulations showed that drug amounts more than 1 mg/mL had yellow sedimentation and loading efficiency was not increased by adding amounts of drug and supernatant, indicating that nanoparticles could not accept amounts more than 1 mg/mL.

Several formulations were prepared and four variables were considered, and the drug loadings were obtained to identify the best loading in order to select one optimum formulation and to characterize the other physical assessments on the optimum one ([Tables 1](#t1-ijn-5-463){ref-type="table"}--[4](#t4-ijn-5-463){ref-type="table"}).

In comparing the results of calculated loadings, increasing the amount of polymer has a marked effect on drug loading ([Table 1](#t1-ijn-5-463){ref-type="table"}).

Amount of the emulsifier has no significant effect on encapsulation of drug but it is necessary for nanoparticle preparation ([Table 2](#t2-ijn-5-463){ref-type="table"}). The volume of internal phase and external phase has a reversal effect on drug loading after volumes of 12 mL and 22 mL, respectively ([Tables 3](#t3-ijn-5-463){ref-type="table"} and [4](#t4-ijn-5-463){ref-type="table"}).

As the results show, the optimum formulation is the one consisting of 165 mg polymer, 50 mg PVA, 12 mL, and 22 mL internal and external phases, respectively, which had a drug content of more than 45%.

The PLGA nanoparticle which is used as control group in comparison of physicochemical characteristics was achieved by 165.27 mg of polymer, 1.31% of emulsifier, 21.33 mL external phase, and 12 mL internal phase volumes. The resulting 9-NC PLGA nanoparticles showed the response to size with average of 207 nm and drug loading of about 33%.[@b7-ijn-5-463]

Nanoparticle characterization
-----------------------------

The morphology of the optimized PLGA-PEG nanoparticles examined by SEM was spherical as shown in [Figure 4](#f4-ijn-5-463){ref-type="fig"}. Average size of nanoparticles was found to be around 148.5 ± 30 nm with a polydispersity of 0.07%. It is concluded that the steric barrier of PEG shell could be the main cause to avoid aggregation of internal phase droplets in preparation pathway; therefore PLGA-PEG nanoparticles have a smaller size than PLGA ones. The zeta potential of the nanoparticles was about +1.84 mV over what is suitable for stable colloidal dispersion of nanoparticles.

The DSC thermograms of 9-NC, PLGA-PEG copolymer, physical mixture of drug and polymer, and 9-NC nanoparticles are shown in [Figure 5](#f5-ijn-5-463){ref-type="fig"}. The DSC curve of 9-NC showed a single melting peak which started to degrade as it melted. The PLGA-PEG thermogram displayed an endothermic peak investigative of polymer transition temperature (Tg). No 9-NC melting peak was visible in the case of drug-loaded nanoparticles. This might be due to the amorphous state of the drug when dispersed in the nanoparticles. Since the curve of copolymer has not any shift in Tg, it is concluded that there is no occurrence of prominent interaction between the drug and copolymer.

Regarding physical mixture, there is not any peak at the melting point of 9-NC. According to glass liquid transition of PLGA-PEG which is at lower temperatures, it is possible that at higher temperatures molecular dispersion of drug in polymer occurs during DSC process.

XRD patterns were used to confirm these results, and these are shown in [Figure 5](#f5-ijn-5-463){ref-type="fig"}. As can be seen, the curves of 9-NC exhibit a sharp peak at about 2θ scattered angle 27 indicating the crystalline nature of 9-NC. This kind of trait was absent in pattern of nanoparticles investigating that 9-NC was not in crystalline form in nanoparticles.

*In vitro* drug release
-----------------------

The 9-NC release profiles from optimum PLGA-PEG nanoparticles are shown in [Figure 6](#f6-ijn-5-463){ref-type="fig"}. The procedure was performed using the dialysis technique using a dialysis membrane having a molecular weight cutoff of 12,000 Da (Sigma, St. Louis, MO) which was fixed on Franz diffusion cell and donor and acceptor medium was PBS (pH 7.4). In the release curve, two parts are seen. The first part shows the initial phase of release which has a rapid trend during the first 5 hours, followed by a distinct prolonged release for more than 120 hours. The rapid initial release can be due to a part of drug on the surface of nanoparticles and the delayed part is thought to be because of diffusion of dissolved drug through polymeric matrix and its exit to the dissolution medium, where as in our previous study about 20% of the drug was released over a period of 20 hours, followed by an extended release period of more than 160 hours (see [Figure 6](#f6-ijn-5-463){ref-type="fig"}). This difference of release profile could be explained by presence of the hydrophilic PEG shell around the nanoparticles, causing increased diffusion of water to the core of particles. On the other hand, compared to plain PLGA nanoparticles, the hydrophilic surface decreases adsorption of lipophilic drugs on the surface of nanoparticles and decreases initial burst drug release.

Release kinetics was evaluated by calculating data via zero order, first order, and Higuchi equations. According to the results, the drug release followed the Higuchi equation and related correlation coefficients were better than both zero and first order kinetics ([Table 5](#t5-ijn-5-463){ref-type="table"}).

Two possible mechanisms according to the Higuchi model may be involved in the release of 9-NC from nanoparticles; the dissolution diffusion of the drug from the matrices and matrix erosion resulting from degradation of polymer.

Baker and Lonsdale developed the equation: 2/3\[1-(1-Q)^2/3^\]-Q = k.t, to describe the release of drug incorporated in a spherical matrix based on a diffusion mechanism.[@b35-ijn-5-463] By fitting the observed data, shown in [Figure 6](#f6-ijn-5-463){ref-type="fig"}, to the spherical matrix model, correlation coefficients of between 0.956 and 0.994 were obtained.

The Hixson --Crowell cube root model, (100-Q.t)^1/3^ = 100^1/3^-K~HC~.t, where K~HC~ is the Hixson--Crowell rate constant, describes the release from the systems, where it depends on the change in surface area and diameter of the particles with time and mainly applies in case of systems, which dissolve or erode over time.[@b36-ijn-5-463] By fitting the release data to this model, correlation coefficients of 0.880--0.937 were obtained.

These results indicate that the release of 9-NC from nanoparticles may be more consistent with a diffusion mechanism than a matrix erosion mechanism. In similar studies, Gao and coworkers prepared different block copolymer micelles of 9-NC, amphiphilic copolymers of methoxy poly(ethylene glycol)-b-poly(D,L-lactide), and copolymers derived from d,l-lactide, trimethylene carbonate, and methylated poly(ethylene glycol).[@b37-ijn-5-463],[@b38-ijn-5-463] These micelles could significantly increase drug solubility; release of 9-NC was nearly zero order after the burst release, and the long hydrophobic chain length led to slower release rate about 50% over 60 hours, similar to results gained in our experiment.[@b37-ijn-5-463],[@b38-ijn-5-463]

In general, *in vitro* release profiles shows that these nanoparticles have the capacity to successfully release 9-NC using a sustained rate.

Conclusion
==========

In this investigation, PLGA-PEG nanoparticles loaded with 9-NC (a novel potent anticancer drug) were prepared by nanoprecipitation, and the physicochemical characteristics included an investigation of their properties, such as drug loading, morphology, size, and thermal behavior were evaluated and compared with the results of our previous study, in which these NPs were prepared using PLGA polymer instead of PLGA-PEG copolymer. The images of SEM indicated the optimized NPs were spherical in shape without any aggregation or adhesion. More detailed studies showed that the particle size of NPs through using PLGA-PEG is smaller than PLGA samples. Drug loading was much higher than the previous study, and the initial release was slower. But as mentioned above the total release was faster than PLGA NPs, which can be explained by the hydrophilic characteristic of PLGA-PEG copolymer. This point causes a rapid release compared with PLGA that is a lipophil polymer and can keep the drug longer than PLGA-PEG copolymer.

Overall physical evaluation comparison shows that PLGA-PEG nanoparticles can be a promising controlled release delivery system of lipophilic drugs like 9-NC specially in cancer therapies which need an acute and target treatment during therapeutically period.

However, the *in vivo* behavior of drug release, the speed of clearance, and final biodistribution of nanoparticles also need to be confirmed in future studies.
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###### 

Results of drug loadings according to amount of polymer (n = 3)

  **Formulation**   **Polymer (mg)**   **PVA (mg)**   **Int. phase (mL)**   **Ext. phase (mL)**   **EE (%)**
  ----------------- ------------------ -------------- --------------------- --------------------- ------------
  1                 50                 50             12                    22                    13.5 ± 3.7
  2                 100                50             12                    22                    15.6 ± 2.7
  3                 125                50             12                    22                    22.3 ± 3.4
  4                 150                50             12                    22                    28.7 ± 2.3
  5                 165                50             12                    22                    45.3 ± 2.9
  6                 180                50             12                    22                    33.3 ± 2.1
  7                 200                50             12                    22                    31.3 ± 4.8
  8                 250                50             12                    22                    28.9 ± 3.1
  9                 300                50             12                    22                    26.5 ± 1.9

**Abbreviations:** EE, entrapment efficacy; PVA, polyvinyl alcohol.

###### 

Results of drug loadings according to amount of surfactant (n = 3)

  **Formulation**   **Polymer (mg)**   **PVA (mg)**   **Int. phase (mL)**   **Ext. phase (mL)**   **EE (%)**
  ----------------- ------------------ -------------- --------------------- --------------------- ------------
  1                 165                0              12                    22                    --
  2                 165                25             12                    22                    18.2 ± 5.8
  3                 165                35             12                    22                    23.4 ± 6.2
  4                 165                50             12                    22                    45.3 ± 2.9
  5                 165                75             12                    22                    28.8 ± 4.9
  6                 165                100            12                    22                    15.2 ± 4.2

**Abbreviations:** EE, entrapment efficacy; PVA, polyvinyl alcohol.

###### 

Results of drug loadings according to internal phase volume (n = 3)

  **Formulation**   **Polymer (mg)**   **PVA (mg)**   **Int. phase (mL)**   **Ext. phase (mL)**   **EE (%)**
  ----------------- ------------------ -------------- --------------------- --------------------- -------------
  1                 165                50             5                     22                    --
  2                 165                50             10                    22                    35.89 ± 4.2
  3                 165                50             12                    22                    45.3 ± 2.9
  4                 165                50             15                    22                    23.4 ± 4.7
  5                 165                50             25                    22                    11.7 ± 4.3

###### 

Results of drug loadings according to amount of external volume (n = 3)

  **Formulation**   **Polymer (mg)**   **PVA (mg)**   **Int. phase (mL)**   **Ext. phase (mL)**   **EE (%)**
  ----------------- ------------------ -------------- --------------------- --------------------- ------------
  1                 165                0              12                    5                     --
  2                 165                25             12                    10                    10.1 ± 6.9
  3                 165                35             12                    20                    13.1 ± 5.2
  4                 165                50             12                    22                    45.3 ± 2.9
  5                 165                75             12                    25                    38.3 ± 7.4
  6                 165                100            12                    30                    30.0 ± 8.6

###### 

Results of release kinetics according to zero order, first order, and Higuchi equations

  **K^a^~h~ μg/h^0.5^**   **Regression coefficient (*R*^2^)**           
  ----------------------- ------------------------------------- ------- -------
  4.351                   0.989                                 0.922   0.896
